UBS Group
VERV

UBS Group’s Verve Therapeutics VERV Stock Holding History

UBS Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,870,522
Closed -$21M – 10970
2025
Q2 		$21M Buy
1,870,522
+1,738,749
+1,320% +$9.91M ﹤0.01% 2310
2025
Q1 		$602K Sell
131,773
-8,016
-6% -$53.7K ﹤0.01% 5708
2024
Q4 		$788K Sell
139,789
-24,338
-15% -$137K ﹤0.01% 5491
2024
Q3 		$794K Buy
164,127
+57,425
+54% +$334K ﹤0.01% 4856
2024
Q2 		$521K Sell
106,702
-185,282
-63% -$1.16M ﹤0.01% 4969
2024
Q1 		$3.88M Buy
291,984
+88,633
+44% +$1.18M ﹤0.01% 3244
2023
Q4 		$2.83M Buy
203,351
+120,088
+144% +$1.49M ﹤0.01% 3439
2023
Q3 		$1.1M Sell
83,263
-4,811
-5% -$77.5K ﹤0.01% 3978
2023
Q2 		$1.65M Sell
88,074
-2,761
-3% -$46K ﹤0.01% 3714
2023
Q1 		$1.31M Sell
90,835
-152,939
-63% -$2.99M ﹤0.01% 3860
2022
Q4 		$4.72M Buy
243,774
+210,071
+623% +$5.57M ﹤0.01% 2555
2022
Q3 		$1.16M Buy
33,703
+33,553
+22,369% +$1.07M ﹤0.01% 3636
2022
Q2 		$2K Sell
150
-106,101
-100% -$1.64M ﹤0.01% 9627
2022
Q1 		$2.42M Buy
106,251
+81,921
+337% +$2.34M ﹤0.01% 3249
2021
Q4 		$897K Buy
24,330
+21,030
+637% +$883K ﹤0.01% 4486
2021
Q3 		$155K Buy
3,300
+1,769
+116% +$104K ﹤0.01% 5518
2021
Q2 		$92K Buy
+1,531
New +$63.5K ﹤0.01% 5956

Other funds holding VERV

GCM
Greenland Capital Management New York $812M AUM 45.54% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group's VERV Position: Q3 2025 in Review

UBS Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 1,870,522 shares — an estimated $21M sold.

UBS Group first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $21M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • UBS Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 1,870,522 Verve Therapeutics shares in Q3 2025, an estimated $21M.
  • UBS Group first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • UBS Group's Verve Therapeutics position peaked at $21M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.